Get the Stockscreener App
1.36
8.11%
-0.12
After Hours:
1.36
Ernexa Therapeutics Inc stock is traded at $1.36, with a volume of 31,966.
It is down -8.11% in the last 24 hours and down -15.53% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$1.48
Open:
$1.47
24h Volume:
31,966
Relative Volume:
0.01
Market Cap:
$10.67M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.1637
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
+3.03%
1M Performance:
-15.53%
6M Performance:
-42.62%
1Y Performance:
-68.71%
1-Day Range:
$1.3423
$1.47
1-Week Range:
$1.22
$1.50
52-Week Range:
$1.09
$14.40
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.36 | 11.62M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com
Ernexa Therapeutics stock falls after ASH meeting presentation By Investing.com - Investing.com Canada
Ernexa Therapeutics Presents New Preclinical Data on ERNA-101 at ASH Annual Meeting Highlighting Innovative Cell Therapy Potential to Combat Cancer - Quiver Quantitative
Ernexa reports promising preclinical data for cancer cell therapy - Investing.com
Ernexa reports promising preclinical data for cancer cell therapy By Investing.com - Investing.com UK
Ernexa Therapeutics Presents New Preclinical Data at - GlobeNewswire
Ernexa Therapeutics (ERNA) Stock Analysis Report | Financials & Insights - Benzinga
With Ernexa Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Can Ernexa Therapeutics Stock Recover If Markets Fall? - Trefis
Ernexa Therapeutics Inc. (ERNA) 5.2% in After-hours: Strong Presentation Initiative - Stocks Telegraph
Ernexa Therapeutics announces oral presentation at the 67th American Society of Hematology - marketscreener.com
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Can Ernexa Therapeutics Inc. stock hit analyst price targetsWeekly Stock Recap & AI Powered Trade Plan Recommendations - Newser
How Ernexa Therapeutics Inc. stock compares to market leadersTrade Analysis Summary & Verified Stock Trade Ideas - Newser
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG - markets.businessinsider.com
Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board By Investing.com - Investing.com Australia
Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board - Investing.com
Ernexa Therapeutics Appoints Dr. Ira S. Winer to Scientific and Medical Advisory Board - Quiver Quantitative
Ernexa Therapeutics Strengthens Scientific and Medical - GlobeNewswire
Profit Review: How Ernexa Therapeutics Inc. stock compares to industry benchmarks2025 Historical Comparison & Fast Moving Trade Plans - BỘ NỘI VỤ
Contrasting Ernexa Therapeutics (NASDAQ:ERNA) & KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
How Ernexa Therapeutics Inc. stock reacts to oil pricesJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
How to monitor Ernexa Therapeutics Inc. with trend dashboardsTrade Entry Summary & Low Risk Entry Point Tips - newser.com
Ernexa Therapeutics Inc. stock chart pattern explained2025 Market Outlook & Verified Momentum Stock Alerts - newser.com
Sector ETF performance correlation with Ernexa Therapeutics Inc.Gap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Is it too late to sell Ernexa Therapeutics Inc.Earnings Risk Report & AI Enhanced Trading Alerts - newser.com
Will Ernexa Therapeutics Inc. bounce back from current supportGold Moves & Real-Time Stock Entry Alerts - newser.com
Why Ernexa Therapeutics Inc. stock could see breakout soonTrend Reversal & Weekly Setup with High ROI Potential - newser.com
Analyzing drawdowns of Ernexa Therapeutics Inc. with statistical toolsGap Down & Long-Term Safe Investment Plans - newser.com
Will Ernexa Therapeutics Inc. stock benefit from automationEntry Point & AI Powered Buy/Sell Recommendations - newser.com
Should I hold or sell Ernexa Therapeutics Inc. stock in 2025Forecast Cut & Free Growth Oriented Trading Recommendations - newser.com
Why Ernexa Therapeutics Inc. stock is a value investor pickJuly 2025 WrapUp & High Accuracy Swing Trade Signals - Fundação Cultural do Pará
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ernexa Therapeutics Inc Stock (ERNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):